Windlas Biotech Q1FY26 – Pharma CDMO with 20% Sales Growth, 31% PAT Growth, and Injectables Ki Nayi Chakkar
1. At a Glance
Windlas Biotech (CMP: ₹908, Mcap: ₹1,911 Cr) is that low-key smallcap CDMO which quietly cooked up 20% YoY sales growth and 31% PAT growth this quarter. EPS annualises to ₹33.7, giving a P/E of ~27× against an industry average of 32.6×. ROCE stands at 17%, ROE 12.8% — decent but not drool-worthy. In the last 6 months, stock fell 13%, but 1-year returns are 9%. Dividend yield? 0.64%, enough to buy a chai-biscuit combo once a year. Debt is negligible (₹32 Cr), so at least bankers aren’t camping outside their office.
2. Introduction
India’s pharma sector is like IPL auctions — flashy bids, big players, and then one silent underdog. Windlas Biotech is that uncapped player who suddenly scores a 50 on debut. They don’t sell medicines under their own name (so your chemist uncle won’t recognise them), but they’re busy behind the curtains manufacturing for Pfizer, Sanofi, Cadila, Intas, etc.
Their bread and butter is complex generics in chronic therapies (anti-diabetic, cardiac, neuropsychiatry). Translation: stuff Indians are unfortunately consuming daily thanks to sedentary lifestyle + Swiggy discounts.
The company also runs a “Trade Generics” business — 280 brands in semi-urban India, piggybacking on Jan Aushadhi Yojana. Basically, they are selling no-frills medicines where “affordable” matters more than “brand recall.”
And the latest masala? Injectables facility. High margins, high risks. One USFDA compliment = multibagger story. One warning letter = shaadi ka band baj gaya.
3. Business Model – WTF Do They Even Do?
Think of Windlas as a three-course thali:
Generic Formulations CDMO (75% rev) – Tablets, capsules, powders manufactured for top pharma giants. They do the dirty work, clients take the glamour.
Trade Generics & Institutional (21% rev) – 280 brands, 996 distributors, sold in Tier-2/3 towns. High volume, low margin, perfect for Bharat.
Exports (4% rev) – Baby steps into global markets. Currently semi-regulated regions, but EU-GMP and SAPHRA approvals give hope.
They’ve got five WHO-GMP compliant plants in Dehradun with 7.3 bn tablet/capsule capacity. R&D spend of ₹7.9 Cr in FY24 resulted in 3,190 new approvals (up from 1,901). Basically, they’re sweating brains, not just machines.
Question for you: If you swallow a pill daily for BP, would you care if it’s manufactured by Windlas or Pfizer, or does only price decide?
4. Financials Overview
Source table
Metric
Q1FY26
Q1FY25
Q4FY25
YoY %
QoQ %
Revenue
₹210 Cr
₹175 Cr
₹203 Cr
+20.0%
+3.4%
EBITDA
₹27 Cr
₹21 Cr
₹26 Cr
+28.6%
+3.8%
PAT
₹17.7 Cr
₹13.5 Cr
₹16 Cr
+31.0%
+10.6%
EPS (₹)
8.43
6.45
7.77
+30.7%
+8.5%
Annualised EPS: ₹33.7. Re-calc P/E: 26.9×.
Commentary: Sales growth like Shah Rukh Khan’s comeback year, margins stable at 13% OPM. EPS rising in sync with PAT shows it’s not accounting jugglery.
